ANNX
$5.61
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Intraday
Recent News
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference
Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and CEO Douglas Love emphasizing upcoming clinical catalysts, ongoing regulatory work, and preparations f
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX?
Earlier this month, Annexon submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart to treat Guillain-Barre syndrome, supported by randomized studies showing rapid effects on neuroinflammation and disability measures. The filing, alongside plans for a U.S. Biologics License Application and broader FORWARD study, positions tanruprubart as a potential first-in-class option in a disease with no FDA-approved treatments. We’ll now examine how Annexon’s...
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome
Annexon (ANNX) is back in focus after the company submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart in Guillain Barre syndrome, marking a key regulatory moment for this clinical program. See our latest analysis for Annexon. The MAA news arrives after a strong 90-day share price return of 92.09% and a 30-day share price return of 17.41%, pointing to building momentum despite a 1-day share price dip of 1.46% and mixed longer term total shareholder...
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead
Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of late-stage and mid-stage milestones that CEO Doug Love described as setting up 2026 as a “pivotal year” for the company. Love highlighted two registration-stage programs—ANX007 in geo
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event just 48 hours away, you can bet the trading volume will fall off a cliff. Wednesday will be a day for the junior ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More